-
A Study to Measure Markers of Immune Tolerance to Predict Women at Risk of Miscarriage or Failed Embryo Transfer
Rochester, MN
The purpose of this study is:
Infertility Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D at the time of embryo transfer in patients undergoing in vitro fertilization are predictive of the cycle outcome: live birth or no live birth
Spontaneous Conception Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D early in the first trimester of gestation are predictive of miscarriage or live birth.
-
Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies (VANISH)
Rochester, MN
Panorama® is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Panorama analyzes SNPs to distinguish maternal from fetal (placental) DNA, targeting 13,932 SNPs covering chromosomes 21, 18, 13, X and Y, to determine chromosomal abnormalities and fetal sex. Panorama is used in twin pregnancies to screen for a variety of abnormalities, including trisomies 21, 18 and 13, monosomy X zygosity and fetal sex for each twin.
The primary objectives of this study are to use the Panorama® testing to:
1) Develop a new algorithm and methodology that ...
-
A Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Who Took Biologics
Rochester, MN
This study is conducted to determine whether the rates of birth defects, miscarriages, premature births and other outcomes in women with inflammatory bowel disease (IBD) taking azathioprine/6MP or biologic therapy (Remicade®, Humira®, Cimzia™, Tysabri®, or Stelara®) are different from those among IBD - affected women not taking these medications.
-
Microbiome Role in Non-Cancerous Reproductive Tract Disorders
Rochester, MN
The aim is the characterization of the microbiome of subjects experiencing benign reproductive tract disorders and its comparison to the microbiome present in individuals lacking that disorder.